Biogen Canada Fails to Secure Reimbursement Deal for Skyclarys
BIIB sits 63% above its 52-week low of $121.05.
Summary
Biogen Canada announced it failed to reach a reimbursement agreement with the Pan-Canadian Pharmaceutical Alliance for its Friedreich's Ataxia drug, Skyclarys. This outcome means Skyclarys will face significant challenges in gaining market access and reimbursement across Canada, limiting its commercial potential in the region. This represents a setback for the drug's global sales outlook, contrasting with several recent positive developments for Biogen's broader pipeline and M&A activity.
At the time of this announcement, BIIB was trading at $197.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.3B. The 52-week trading range was $121.05 to $205.97. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.